home-slider-london-desktop.jpg home-slider-london-mob.jpg
About us About us
About us We have diligently served the interests of clients for over 100 years. Find Out More
Hargreave Hale SIPP Hargreave Hale SIPP
Hargreave Hale SIPP Allowing you the freedom to choose and manage a wide range of investments Find Out More
Inheritance Tax Portfolio Service Inheritance Tax Portfolio Service
Inheritance Tax Portfolio Service Designed to reduce the effect of Inheritance Tax Find Out More

Please choose from the service options below. If you are unsure, please confirm if you are an Intermediary, Direct Investor or a Corporate Client and we will identify the services most relevant to you.

In the news

TRUSTNET

CUTTING BACK MY UK EXPOSURE

07.07.2017
In the news

Investment Week

Economic improvements favour Smaller Caps

12.06.2017
In the news

East Anglian Daily Times

Sit Tight

09.06.2017
Market News

IWG buys back shares

18.08.2017

IWG bought back 250,000 ordinary shares yesterday at prices ranging from 305.2p to 301.6p apiece to be held in treasury. At 9:20am: (LON:IWG) IWG Plc share price was -3.3p at 300.2p Story provided by StockMarketWire.com

IWG bought back 250,000 ordinary shares yesterday at prices ranging from 305.2p to 301.6p apiece to be held in treasury. At 9:20am: (LON:IWG) IWG Plc share price was -3.3p at 300.2p Story provided by StockMarketWire.com

Market News

UPDATE: Euro/Dollar unchanged @ 1.1732

18.08.2017

Euro/Dollar unchanged @ 1.1732


Story provided by StockMarketWire.com

Euro/Dollar unchanged @ 1.1732


Story provided by StockMarketWire.com

Market News

Destiny Pharma to float on AIM

18.08.2017

Destiny Pharma, a clinical stage biotechnology company focused on the development of new anti-microbial drugs, intends to float on AIM. The company also announced a proposed placing and said the amount of capital raised would be determined in the coming days. Chief executive Neil Clark said: "The rise of anti-microbial resistance is recognised globally as a major issue that urgently needs addressing and our XF-drug platform offers a novel way of tackling this. "The funds we intend to raise ...

Destiny Pharma, a clinical stage biotechnology company focused on the development of new anti-microbial drugs, intends to float on AIM. The company also announced a proposed placing and said the amount of capital raised would be determined in the coming days. Chief executive Neil Clark said: "The rise of anti-microbial resistance is recognised globally as a major issue that urgently needs addressing and our XF-drug platform offers a novel way of tackling this. "The funds we intend to raise in conjunction with the admission of our shares to trading on AIM should allow us to progress our lead drug candidate, XF-73, to the cusp of phase III pivotal studies in the prevention of post-surgical Staphylococcus aureus infections during 2019. "This should be a key value inflection point as, if successful, our drug would be the first to be specifically labelled for this new US FDA sanctioned indication; a market we believe to be worth a billion dollars in the US alone and growing." Story provided by StockMarketWire.com

Market News

Malvern makes first half loss of £390,000

18.08.2017

Malvern International made a loss before tax of £390,000 in the first half, compared with a loss of £460,000 the previous year. Revenues on continuing activities fell to £1.65m from £2.07m the year before. The company said London has started to recover from the severe losses it incurred in previous years to a small loss for the first half. Singapore received its EduTrust certification from the Committee of Private Education in July 2017 and initiatives to capitalize on the re-certificatio...

Malvern International made a loss before tax of £390,000 in the first half, compared with a loss of £460,000 the previous year. Revenues on continuing activities fell to £1.65m from £2.07m the year before. The company said London has started to recover from the severe losses it incurred in previous years to a small loss for the first half. Singapore received its EduTrust certification from the Committee of Private Education in July 2017 and initiatives to capitalize on the re-certification have already been implemented. Malaysia, while down in the first-half due to a correction and improvement in quality assurance and international student issues, is now showing signs of improvement with a better outlook expected for the second half of this financial year. At 9:11am: (LON:MLVN) Malvern International Plc Ord 5p share price was 0p at 2.38p Story provided by StockMarketWire.com

Indices